Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

SUMMARY: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained...

Descripción completa

Detalles Bibliográficos
Autores principales: Watts, N.B., Dore, R.K., Baim, S., Mitlak, B., Hattersley, G., Wang, Y., Rozental, T.D., LeBoff, M.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755646/
https://www.ncbi.nlm.nih.gov/pubmed/32935170
http://dx.doi.org/10.1007/s00198-020-05555-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755646/
https://www.ncbi.nlm.nih.gov/pubmed/32935170
http://dx.doi.org/10.1007/s00198-020-05555-1

Ejemplares similares